Entitlement Offer - Extension of Closing Date
Released
Released
Announcement PDF
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
27 March 2023
Non-renounceable Entitlement Offer - Extension of Closing Date
MELBOURNE – Imagion Biosystems (ASX:IBX, Imagion or the Company) refers to its announcement
titled 'Non-renounceable Entitlement Offer' dated 7 March 2023 in relation to the pro rata nonrenounceable entitlement offer to existing eligible shareholders to raise up to $2.4 million through the offer
of one (1) new fully paid ordinary shares in the Company for every eight (8) shares held by eligible
shareholders registered at 10 March 2023 at an issue price of $0.017 per share (Offer).
Capitalised terms used in this announcement but not defined have the meaning given to them in the Offer
Document released to ASX on 7 March 2023, unless the context requires otherwise.
The Company advises that the Closing Date for the Offer has been extended to 14 April 2023.
The revised indicative timetable for the Offer is set out below.
Event
Date
Record Date (to determine Entitlement of Eligible
Shareholders to participate in the Offer)
7.00pm (AEDT), 10 March 2023
Opening Date of Entitlement Offer - Dispatch of the Eligible
Shareholder's letter advising them of the access details for
the Offer Document and online Entitlement & Acceptance
Form.
Closing Date for acceptances under the Entitlement Offer
15 March 2023
5.00pm (AEDT), 14 April 2023
Shortfall (if any) announced to the ASX
19 April 2023
Issue of the New Shares
21 April 2023
Trading (T+2) of New Shares expected to commence
24 April 2023
* The above dates are indicative only and subject to change. The Company reserves the right, subject to the
Corporations Act and the Listing Rules, to further change the Closing Date or to withdraw the Offer at any time without
prior notice, in which case all Application Monies will be refunded (without interest) as soon as practicable. Any
extension of the Closing Date will have a consequential effect on the issue date of New Shares. All dates and times
are references to Melbourne, Australia time.
Applications for New Shares under the Offer may only be made by following instructions on the Entitlement
& Acceptance Form which has been made accessible online to Eligible Shareholders. Shareholders
eligible to participate in the Offer should read the Offer Document carefully and consult their professional
advisers as necessary.
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
-ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging
technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other
diseases earlier and with higher specificity than is currently possible.
For further information please visit www.imagionbiosystems.com
Authorisation & Additional information
This announcement was authorised by the Board of Directors of Imagion Biosystems Limited
U.S. Media Contact:
Casie Ost
Casie.ost@imagionbio.com
+1-619-693-4428
Australian Media & Investor Relations:
Hannah Howlett, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 (0) 450648064
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com
Share your feedback
Discover